Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS4131 Combined With Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia
NCT07903623Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of QLS4131 in plasma cell leukaemia (PCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Oct 2026; status: recruiting.
02
Drugs
QLS4131
03
Conditions
plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on NCT07903623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903623.